Anti-TGFBI targeting therapies may therefore prove to be an effective strategy, possibly in combination with other treatments.172 Furthermore, using combined inhibition of both TGF-β and PDL-1 has been shown to abrogate primary and metastatic tumour immune evasion in murine models of CRC and improved their survival. This evidence concerns the gene TGFB1 and colorectal carcinoma.